In this study, pre- and postsurgical specimens of cell-free DNA from women with newly diagnosed endometrial cancer were subjected to ultra-high depth sequencing.
The search for molecular precursors of cancer in the fallopian tubes is largely driven by emerging evidence supporting it as the site of origin for many ovarian cancers.
This study evaluated the rates of germline and somatic BRCA testing in women with ovarian cancer included in the Flatiron Health database.
Data used in this study were accessed from the National Inpatient Sample, which is sponsored by the Agency for Healthcare Research and Quality.
PAOLA-1/ENGOT-ov25 is a phase 3 clinical trial evaluating a first-line olaparib plus bevacizumab maintenance regimen in patients with advanced ovarian cancer.
This analysis presents preliminary data for secondary endpoints of TFST and PFS2 from the phase 3 PRIMA/ENGOTOV26/GOG-3012 study.
JAVELIN Ovarian 100 was the first phase 3 study to evaluate an immune checkpoint inhibitor in previously untreated advanced epithelial ovarian cancer.
NCCN Ovarian Cancer Guidelines include a recommendation for somatic and genetic testing following a genetic risk evaluation for all women with the disease.
In the United States, the mortality rate associated with uterine cancer is approximately twice as high for black women compared with white women.
It has been estimated that approximately 30% of patients with advanced uterine serous carcinoma have HER2-positive disease.
